Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · see citing works

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works

Association of nonalcoholic fatty liver disease with insulin resistance

Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,564 · see citing works

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429 · see citing works

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · see citing works

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

Mofrad, P., Contos, M., Haque, M., Sargeant, C. C., Fisher, R., Luketic, V., Sterling, R., Shiffman, M., Stravitz, R., & Sanyal, A. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,221 · see citing works

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c

Ferré, P., & Foufelle, F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01275.x · Cited by 704 · see citing works

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

Fracanzani, A., Valenti, L. N., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., Bertelli, C., Fatta, E., Bignamini, D., Marchesini, G., et al. (2008) · Hepatology · doi:10.1002/hep.22429 · Cited by 692 · see citing works

A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver

Yamashita, H., Takenoshita, M., Sakurai, M., Bruick, R. K., Henzel, W. J., Shillinglaw, W., Arnot, D., & Uyeda, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161284298 · Cited by 682 · see citing works

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis

Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 634 · see citing works

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials: Hepatology

Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · see citing works

High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels

Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503 · see citing works

One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study

Huang, M. A., Greenson, J. K., Chao, C., Anderson, L., Peterman, D., Jacobson, J. A., Emick, D. M., Lok, A. S.-F., & Conjeevaram, H. S. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41334.x · Cited by 445 · see citing works

Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis

Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., & Targher, G. (2017) · Metabolism · doi:10.1016/j.metabol.2017.11.003 · Cited by 348 · see citing works

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

Loomba, R. S., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J. C., Kono, Y., Bhatt, A., et al. (2014) · Hepatology · doi:10.1002/hep.27647 · Cited by 346 · see citing works

SGLT inhibitors in management of diabetes

Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 333 · see citing works

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

Cui, J. Y., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 327 · see citing works

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 312 · see citing works

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299 · see citing works

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches

Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256 · see citing works

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

Le, T., Chen, J., Changchien, C., Peterson, M. R., Kono, Y., Patton, H. M., Cohen, B. L., Brenner, D. A., Sirlin, C. B., & Loomba, R. S. (2012) · Hepatology · doi:10.1002/hep.25731 · Cited by 244 · see citing works

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151511 · Cited by 230 · see citing works

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD

Bazick, J., Donithan, M., Neuschwander‐Tetri, B. A., Kleiner, D. E., Brunt, E. M., Wilson, L., Doo, E., Lavine, J. E., Tonascia, J., & Loomba, R. S. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206 · see citing works

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195 · see citing works

Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study

Shibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 192 · see citing works

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective

Gusdon, A. M., Song, K., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 171 · see citing works

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., Kato, S., Mawatari, H., Fujita, K., Yoneda, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146337 · Cited by 170 · see citing works

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

Patel, J. R., Bettencourt, R., Cui, J. Y., Salotti, J., Hooker, J. C., Bhatt, A., Hernandez, C., Nguyen, P., Aryafar, H., Valasek, M. A., et al. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16656735 · Cited by 163 · see citing works

Association between novel MRI ‐estimated pancreatic fat and liver histology‐determined steatosis and fibrosis in non‐alcoholic fatty liver disease

Patel, N. S., Peterson, M. R., Brenner, D. A., Heba, E. R., Sirlin, C. B., & Loomba, R. S. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12237 · Cited by 127 · see citing works

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., Mori, K., Matsunaga, Y., Yamamotoya, T., Kamata, H., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0102-8 · Cited by 113 · see citing works

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Akuta, N., Watanabe, C., Kawamura, Y., Arase, Y., Saitoh, S., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1019 · Cited by 104 · see citing works

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects

Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76 · see citing works

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70 · see citing works

Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis

Reeder, S. B. (2013) · Hepatology · doi:10.1002/hep.26543 · Cited by 50 · see citing works

The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin

Takeda, A., Irahara, A., Nakano, A., Takata, E., Koketsu, Y., Kimata, K., Senda, E., Yamada, H., Ichikawa, K., Fujimori, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8754-16 · Cited by 37 · see citing works

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease

Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529 · see citing works

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2018) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,221 · see citing works

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 837 · see citing works

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Cowie, M., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 805 · see citing works

NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes

Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643 · see citing works

The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)

Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627 · see citing works

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581 · see citing works

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease

Khan, R. S., Bril, F., Cusi, K. J., & Newsome, P. N. (2018) · Hepatology · doi:10.1002/hep.30429 · Cited by 543 · see citing works

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 507 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455 · see citing works

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 393 · see citing works

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works

Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial

Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360 · see citing works

Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease

Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 311 · see citing works

Evolution of NAFLD and Its Management

Mundi, M. S., Velapati, S. R., Patel, J. R., Kellogg, T. A., Dayyeh, B. K. A., & Hurt, R. T. (2019) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 289 · see citing works

Non-alcoholic fatty liver disease: A patient guideline

Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264 · see citing works

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · see citing works

Pharmacotherapy of obesity: available medications and drugs under investigation.

Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248 · see citing works

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615978 · Cited by 243 · see citing works

The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

Caussy, C., Aubin, A., & Loomba, R. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 246 · see citing works

Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management

Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228 · see citing works

NAFLD and liver transplantation: Disease burden, current management and future challenges

Burra, P., Becchetti, C., & Germani, G. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100192 · Cited by 221 · see citing works

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review

Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230 · see citing works

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options

Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 216 · see citing works

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204 · see citing works

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis

Ghanim, H., Abuaysheh, S., HEJNA, J. M., Green, K., Batra, M., Makdissi, A., Chaudhuri, A., & Dandona, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa057 · Cited by 201 · see citing works

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193 · see citing works

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview

Marchisello, S., Pino, A. D., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 194 · see citing works

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 192 · see citing works

Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus

Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191 · see citing works

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Taheri, H., Malek, M., Ismail‐Beigi, F., Zamani, F., Sohrabi, M., Babaei, M. R., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 197 · see citing works

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186 · see citing works

Therapeutic Landscape for NAFLD in 2020

Neuschwander‐Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 183 · see citing works

Management of non-alcoholic fatty liver disease

Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 181 · see citing works

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence

Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s233538 · Cited by 177 · see citing works

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173 · see citing works

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 174 · see citing works

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection

Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 172 · see citing works

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Targher, G., Corey, K. E., & Byrne, C. D. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 170 · see citing works

SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits

Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S. C., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 193 · see citing works

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works

Metabolic liver disease in diabetes – From mechanisms to clinical trials

Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 160 · see citing works

Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications

Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.008 · Cited by 146 · see citing works

Metabolic Targets in Nonalcoholic Fatty Liver Disease

Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 142 · see citing works

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Arab, J. P., Dirchwolf, M., Álvares‐da‐Silva, M. R., Francisco Barrera, M., Benítez, C., Castellanos, M., Castro‐Narro, G., Chávez-Tapia, N. C., Chiodi, D., Cotrim, H. P., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 142 · see citing works

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138 · see citing works

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Pοlyzos, S. A., Kang, E. S., Boutari, C., Rhee, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154203 · Cited by 139 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 136 · see citing works

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation

Marton, A., Kaneko, T., Kovalik, J., Yasui, A., Nishiyama, A., Kitada, K., & Titze, J. M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00350-x · Cited by 133 · see citing works

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 133 · see citing works

Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology

Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 132 · see citing works

Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial

Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., Jiang, H., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 145 · see citing works

Evolving Role for Pharmacotherapy in NAFLD/NASH

Attia, S. L., Softic, S., & Mouzaki, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 130 · see citing works

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 130 · see citing works

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126 · see citing works

Obesity‐related glomerulopathy: Current approaches and future perspectives

Martínez‐Montoro, J. I., Morales, E., Cornejo-Pareja, I. M., Tinahones, F. J., & Fernández‐García, J. C. (2022) · Obesity Reviews · doi:10.1111/obr.13450 · Cited by 121 · see citing works

The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway

Meng, Z., Liu, X., Li, T., Fang, T., Cheng, Y., Han, L., Sun, B., & Chen, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107492 · Cited by 120 · see citing works

SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 118 · see citing works

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?

Tomah, S., Alkhouri, N., & Hamdy, O. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00097-1 · Cited by 117 · see citing works

SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases

Hoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 112 · see citing works

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Kullmann, S., Hummel, J., Wagner, R. J., Dannecker, C., Vosseler, A., Fritsche, L., Veit, R., Kantartzis, K., Machann, J., Birkenfeld, A. L., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1136 · Cited by 112 · see citing works

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota

Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 112 · see citing works

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Wei, Q., Xu, X., Guo, L., Li, J., & Li, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635556 · Cited by 109 · see citing works

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial)

Sumida, Y., Murotani, K., Saito, M., Tamasawa, A., Osonoi, Y., Yoneda, M., & Osonoi, T. (2018) · Hepatology Research · doi:10.1111/hepr.13236 · Cited by 108 · see citing works

Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!

Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 108 · see citing works

The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications

Palma, R., Pronio, A., Romeo, M., Scognamiglio, F., Ventriglia, L., Ormando, V. M., Lamazza, A., Pontone, S., Federico, A., & Dallio, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133649 · Cited by 111 · see citing works

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease

Inoue, M., Hayashi, A., Taguchi, T., Arai, R., Sasaki, S., Takano, K., Inoue, Y., & Shichiri, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12980 · Cited by 105 · see citing works

Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

Duseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 105 · see citing works

Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges

Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 103 · see citing works

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100 · see citing works

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment

Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 109 · see citing works

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 97 · see citing works

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

Badmus, O. O., Hinds, T. D., & Stec, D. E. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01242-8 · Cited by 87 · see citing works

Pharmacological Treatment for Non-alcoholic Fatty Liver Disease

Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 83 · see citing works

Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress

Petito‐da‐Silva, T. I., Souza‐Mello, V., & Barbosa‐da‐Silva, S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110539 · Cited by 81 · see citing works

Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis

Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91 · see citing works

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Seko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184767 · Cited by 80 · see citing works

Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease

Bedi, O., Aggarwal, S., Trehanpati, N., Ramakrishna, G., & Krishan, P. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.10.004 · Cited by 81 · see citing works

A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health

Moolla, A., Motohashi, K., Marjot, T., Shard, A., Ainsworth, M. A., Gray, A. M., Holman, R. R., Pavlides, M., Ryan, J. D., Tomlinson, J., et al. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101155 · Cited by 80 · see citing works

Digital twin-enabled personalized nutrition improves metabolic dysfunction-associated fatty liver disease in type 2 diabetes: results of a 1-year randomized controlled study

Joshi, S., Shamanna, P., Dharmalingam, M., Vadavi, A., Keshavamurthy, A., Shah, L., & Mechanick, J. I. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.08.016 · Cited by 81 · see citing works

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79 · see citing works

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit

Patel, D. K., & Strong, J. L. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 79 · see citing works

Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease

Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 82 · see citing works

The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study

Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01483-y · Cited by 78 · see citing works

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 77 · see citing works

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75 · see citing works

Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials

Xing, B., Zhao, Y., Dong, B., Zhou, Y., Lv, W., & Zhao, W. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13237 · Cited by 75 · see citing works

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Dougherty, J. A., Guirguis, E. H., & Thornby, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 74 · see citing works

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease

Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 75 · see citing works

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association

Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 77 · see citing works

SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization

Lin, X.-F., Cui, X.-N., Yang, J., Jiang, Y.-F., Wei, T.-J., Xia, L., Liao, X.-Y., Li, F., Wang, D.-D., Li, J., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01389-3 · Cited by 69 · see citing works

Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes

Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 69 · see citing works

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 68 · see citing works

Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map

Kumar, J., Memon, R. S., Shahid, I., Rizwan, T., Zaman, M., Menezes, R. G., Kumar, S., Siddiqi, T. J., & Usman, M. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.08.021 · Cited by 68 · see citing works

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68 · see citing works

Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis

Umais, M., Imtiaz, H., Luqman, M. S., Anwar, S., Iftikhar, M. U., Maheshwari, K., Sara, Z. T., Naseem, N. U. H., Ibnath, F. A., Syed, A. R. S., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04493-4

The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease

Pokharel, A., Sudhamshu, K. C., Thapa, P., Karki, N., Shrestha, R., Jaishi, B., & Paudel, M. S. (2021) · Cureus · doi:10.7759/cureus.16687 · Cited by 21 · see citing works

Effect of empagliflozin on liver function in type 2 diabetes: A systematic review and meta-analysis of randomized trials

Rafat, Z., Delpasand, K., & Roostaei, D. (2023) · Journal of Current Biomedical Reports · doi:10.61882/jcbior.4.2.234

Empagliflozin effectively reduces liver fat content in type 2 diabetes

KAHL, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Kantartzis, K., et al. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/s-0039-1688168

133-OR: Effects of Empagliflozin on Liver Fat Content in Type 2 Diabetes: The EMLIFA001 Trial

KAHL, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Kantartzis, K., et al. (2019) · Diabetes · doi:10.2337/db19-133-or · Cited by 1 · see citing works